Loading…
Loading…
Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sharply, its finance chief told Reuters on Tuesday.
Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.
Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls, and regulatory shifts—have driven shares down, but core fundamentals and inelastic product demand remain intact. CLPBY now trades at a historically low sub-18x P/E, offering a 5.76% yield and potential 12–13% annualized growth until 2028E, supporting a buy rating.
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Volatility and Risk Coloplast A/S has a beta
Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs, supports stable, mid-to-high single-digit growth expectations for the long term. Management targets 7–8% organic revenue growth and at least 20% ROIC by FY 2029/30, with current dividend yield above 5% but payout ratio unsustainably high.
No recent filings indexed.